Myo-inositol is sometimes given intravenously for the nutritional management of premature babies. While this is likely safe for the baby,[1][2][3] the current evidence shows that myo-inositol is unlikely to reduce mortality (risk of death) or prevent conditions like retinopathy of prematurity and respiratory distress syndrome when given intravenously to premature babies.[4][3][5]
Does intravenous inositol improve birth outcomes in premature babies?
Written by:
Fact-checked
by:
•Last Updated: April 23, 2025
Myo-inositol is sometimes administered intravenously for premature babies and is considered likely to be safe. However, current evidence suggests that it does not reduce mortality or prevent conditions such as retinopathy of prematurity and respiratory distress syndrome in these infants.